(Q39828343)

15 September 2017

Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry (English)

1 reference

15 September 2017

1 reference

Julie A Stone

1

1 reference

15 September 2017

Christopher Banfield

2

1 reference

15 September 2017

Marc Pfister

3

1 reference

15 September 2017

Stacey Tannenbaum

4

1 reference

15 September 2017

Sandy Allerheiligen

5

1 reference

15 September 2017

Jeffrey D Wetherington

6

1 reference

15 September 2017

Rajesh Krishna

7

1 reference

15 September 2017

Dennis M Grasela

8

1 reference

15 September 2017

1 September 2010

1 reference

The Journal of Clinical Pharmacology

15 September 2017

1 reference

15 September 2017

50

1 reference

15 September 2017

9 Suppl

1 reference

15 September 2017

20S-30S

1 reference

The FDA's critical path initiative: a brief introduction.

15 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Quantitative disease, drug, and trial models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Learning versus confirming in clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Pharmacokinetic/pharmacodynamic modeling in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Model-based drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Concepts and challenges in quantitative pharmacology and model-based drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Model-based drug development: the road to quantitative pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

21 January 2018

Pharmacometrics 2020.

1 reference

https://api.crossref.org/works/10.1177%2F0091270010377628

21 January 2018

Identifiers

DOI

10.1177/0091270010377628

1 reference

15 September 2017

1 reference